Table 6.
Factors associated with the recurrence of HCC after DAA treatment in the late phase (more than 1 year after DAA treatment completion)
| HCC recurrence | No HCC recurrence | Hazard ratio | 95% CI | p-value | |
|---|---|---|---|---|---|
| Age (years) | 73.5 ± 7.0 | 70.6 ± 8.1 | 1.04 | 0.99–1.08 | 0.062 |
| Sex (male/female) | 29/10 | 48/39 | 2.15 | 1.04–4.42 | 0.049 |
| Body mass index (kg/m2) | 23.1 ± 3.2 | 23.3 ± 3.6 | 0.97 | 0.88–1.07 | 0.79 |
| White blood cell count (/μL) | 4435 ± 1641 | 4311 ± 1250 | 1.00 | 0.99–1.00 | 0.64 |
| Platelet count (×104/μL) | 14.8 ± 15.2 | 11.4 ± 4.6 | 1.01 | 0.99–1.03 | 0.064 |
| ALT (U/L) | 45.6 ± 26.1 | 46.7 ± 29.1 | 0.99 | 0.98–1.00 | 0.84 |
| AST (U/L) | 50.7 ± 22.3 | 52.2 ± 28.5 | 0.99 | 0.98–1.00 | 0.76 |
| Total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.4 | 0.75 | 0.35–1.60 | 0.80 |
| Albumin (g/dL) | 3.8 ± 0.4 | 3.8 ± 0.4 | 1.05 | 0.48–2.28 | 0.79 |
| Prothrombin time (%) | 85.1 ± 15.5 | 81.6 ± 16.6 | 1.01 | 0.99–1.03 | 0.28 |
| AFP (ng/mL) | 12.2 ± 14.8 | 17.6 ± 40.9 | 0.99 | 0.97–1.01 | 0.43 |
| eGFR (mL/min/1.73 m2) | 65.1 ± 18.3 | 71.6 ± 19.4 | 0.98 | 1.00–1.02 | 0.020 |
| Total cholesterol (mg/dL) | 152 ± 23 | 151 ± 26 | 1.00 | 0.99–1.02 | 0.85 |
| Diabetes mellitus (no/yes) | 26/12 | 70/17 | 1.77 | 0.89–3.51 | 0.16 |
| Alcohol (none/drinking/unknown) | 32/6/1 | 62/12/3 | 1.29 | 0.74–2.25 | 0.23 |
| FIB-4 index | 4.9 ± 2.5 | 5.7 ± 3.7 | 0.89 | 0.78–1.01 | 0.24 |
| APRI | 1.2 ± 0.7 | 1.5 ± 1.6 | 0.65 | 0.41–1.02 | 0.24 |
| Post-treatment white blood cell count (/μL) | 4964 ± 1465 | 4710 ± 1606 | 1.00 | 0.99–1.00 | 0.41 |
| Post-treatment ALT (U/L) | 21.5 ± 11.9 | 25.0 ± 31.6 | 0.99 | 0.97–1.01 | 0.52 |
| Post-treatment AST (U/L) | 28.4 ± 15.5 | 30.5 ± 20.6 | 0.98 | 0.96–1.01 | 0.58 |
| Post-treatment total bilirubin (mg/dL) | 0.8 ± 0.4 | 0.8 ± 0.4 | 0.78 | 0.35–1.73 | 0.98 |
| Post-treatment albumin (g/dL) | 3.9 ± 0.4 | 3.9 ± 0.3 | 1.03 | 0.48–2.21 | 0.61 |
| Post-treatment prothrombin time (%) | 84.3 ± 13.9 | 82.8 ± 17.3 | 1.00 | 0.98–1.02 | 0.67 |
| Post-treatment AFP (ng/mL) | 6.0 ± 5.3 | 6.6 ± 6.6 | 0.97 | 0.90–1.05 | 0.69 |
| Post-treatment eGFR (mL/min/1.73 m2) | 62.7 ± 19.6 | 70.6 ± 17.0 | 0.98 | 0.96–0.99 | 0.013 |
| SVR/no SVR | 38/1 | 84/3 | 0.78 | 0.10–5.73 | 1.00 |
| Child-Pugh class (A/B/C) | 32/4/0 | 71/12/0 | 0.68 | 0.24–1.93 | 0.77 |
| BCLC stage (0/A/B/C/D) | 19/9/4/6/1 | 39/20/12/15/1 | 0.97 | 0.74–1.28 | 0.94 |
| Number of months from HCC treatment to DAA therapy initiation | 25 ± 34 | 21 ± 23 | 1.00 | 0.99–1.00 | 0.51 |
| Number of curative treatments for HCC | 1.0 ± 1.2 | 0.8 ± 1.4 | 1.13 | 0.89–1.43 | 0.44 |